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Abstract
Genome-wide association studies (GWAS) suggests that a complex disease is typically
affected by many genetic variants with small or moderate effects. Identification of these
risk variants remains to be a very challenging problem. Traditional approaches focus-
ing on a single GWAS dataset alone ignore relevant information that could potentially
improve our ability to detect these variants: (1) Accumulating evidence suggests that
different complex diseases are genetically correlated, i.e., multiple diseases share common
risk genetic bases, which is known as “pleiotropy”. (2) SNPs are not equally important
and functionally annotated genetic variants have demonstrated a consistent pattern of
enrichment. Thus, we proposed a novel statistical approach, named GPA, to performing
integrative analysis of multiple GWAS datasets and functional annotations. Hypothesis
testing procedures were developed to facilitate statistical inference of pleiotropy and en-
richment of functional annotation. A computationally efficient EM algorithm was also
available to handle millions of SNP markers. Notably, our approach takes SNP-wise p
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values from traditional GWAS analysis as input, making it especially useful when only
SNP summary statistics are available but not the genotype and phenotype data. We ap-
plied our approach to perform systematic analysis of five psychiatric disorders. Not only
did GPA identify many weak signals missed by the original single phenotype analysis, but
also revealed interesting genetic architectures of these disorders. the pleiotropic effect was
detected among these among psychiatric disorders, and the SNPs in the central nervous
system genes were significantly enriched. These results deepened our understanding of ge-
netic etiology for psychiatric disorders. We also applied GPA to the bladder cancer GWAS
data with the ENCODE DNase-seq data from 125 cell lines and showed that GPA can
detect cell lines that are more biologically relevant to the phenotype of interest. In sum-
mary, GPA can serve as an effective tool for integrative data analysis in the post-GWAS
era.
1 Introduction
Hundreds of genome-wide association studies (GWAS) have been conducted to study the genetic
bases of complex human traits/diseases. As of Dec., 2013, more than 11,000 single-nucleotide
polymorphisms (SNPs) have been reported to be significantly associated with at least one
complex traits/diseases (see the web resource of GWAS catalog [11] http://www.genome.gov/
gwastudies/). Despite of these successes of GWAS, these significantly associated SNPs can
only explain a small portion of genetic contributions to complex traits/diseases [18]. For ex-
ample, human height is a highly heritable trait whose heritability is estimated to be around
80%, i.e., 80% of variation in height within the same population can be attributed to genetic
effects [39]. Based on large-scale GWAS, about 180 SNPs have been reported to be significantly
associated with human height [1]. However, these loci together can only explain about 5-10%
of variation in height [1, 18, 37]. This phenomenon is referred to as “the missing heritability”
[16, 17, 18].
Finding the missing heritability has drawn much attention from worldwide researchers. The
role of common variants (minor allele frequency (MAF) ≥ 0.01) has been shown to be critical in
explaining the phenotypic variance. Instead of only using genome-wide significant SNPs, Yang
et al. [41] reported that, by using all genotyped common SNPs, 45% of the variance for human
height can be explained. This result suggests that a large proportion of the heritability is not
actually missing: given the limited sample size, many individual effects of genetic markers are
too weak to pass the genome-wide significance, and thus those variants remain undiscovered.
So far, people have found similar genetic architectures for many other complex traits/diseases
[38], such as metabolic syndrome traits [36] and psychiatric disorders [5, 12], i.e., the phenotype
is affected by many genetic variants with small or modest effects, which is usually referred to
as “polygenicity”. The polygenicity of complex traits is further supported by recent GWAS
with larger sample sizes, in which more associated common SNPs with moderate effects have
been identified (e.g., [20]). Clearly, the emerging polygenic genetic architecture imposes a great
challenge of identifying risk genetic variants: a larger sample size is required to identify genetic
variants with smaller effect sizes. However, sample recruitment may be expensive and time-
consuming. Alternatively, integrative analysis of genomic data could be a promising direction,
including combining GWAS data of multiple genetically related phenotypes and incorporating
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relevant biological information.
The last couple of years have seen an emerging recognition of “pleiotropy”, i.e. the sharing
of genetic factors, between human complex traits/diseases. For example, a systematic analysis
of the NHGRI catalog (http://www.genome.gov/gwastudies/) of published GWAS showed
that 16.9% of the reported genes and 4.6% of the reported SNPs are associated with multi-
ple traits/diseases [30]. Through a “pleiotropic enrichment” method, Andreassen et al showed
that it is possible to improve the power to detect schizophrenia-associated genetic variants by
utilizing the pleiotropy between schizophrenia (SCZ) and cardiovascular-disease [2]. A more
recent study identified four significant loci (p-value < 5× 10−8) to be pleiotropic by analyzing
GWAS data of 33,332 cases and 27,888 controls for five psychiatric disorders [6]. Further anal-
ysis suggested very significant genetic correlation between schizophrenia and bipolar disorder
(0.68± 0.04 s.e.) [5]. The wide-existing pleiotropy has also been demonstrated among several
other types of traits, for example, metabolic syndrome traits [36] and cancers [26].
An increasing number of studies also suggest that functionally annotated SNPs are gen-
erally more biologically important and henceforth more likely to be associated with complex
traits/diseases. To name a few, Schork et al. [27] demonstrated a consistent pattern of en-
richment of GWAS signals among functionally annotated SNPs, using GWAS data of different
traits/diseases (e.g., Crohn’s disease and SCZ). Yang et al. [43] showed that SNPs in the genic
region could explain more variance of height and body mass index (BMI) than SNPs in the in-
tergenic region. Nicolae et al. [22] suggested that SNPs associated with complex traits/disease
were more likely to be expression quantitative trait loci (eQTL). In addition, public availability
of the vast amount of functional annotation data also provides unprecedented opportunities to
investigate the enrichment of GWAS signals among these various types of functional annota-
tions. For example, recently, the Encyclopedia of DNA Elements (ENCODE) Consortium has
generated vast amounts of experimental data on gene expression (RNA-seq), DNA methylation
status (RRBS-seq), chromatin modifications (ChIP-seq), chromatin accessibility (DNase-seq
and FAIRE-seq), transcription factor (TF) binding sites (ChIP-seq), and long-range chromatin
interactions (ChIA-PET, Hi-C, and 5C). As of September 2012, more than 1,600 data sets from
147 cell lines have been produced to annotate human genome, including 2.89 million unique,
non-overlapping DNase I hypersensitivity sites (DHSs) in 125 cell lines using DNase-seq and
630K binding regions of 119 DNA-binding proteins in 72 cell lines using ChIP-seq, among
many [34]. The ENCODE Project Consortium [34] examined 4,492 risk-associated SNPs from
NHGRI GWAS catalog and found that 12% of them overlap with TF binding regions and 34%
overlap with DHSs.
The widely existing pleiotropy between complex traits/diseases and increasingly rich func-
tional annotation data are calling for novel statistical methods to effectively perform joint
analysis of multiple GWAS data sets and functional annotation data. Statistical methods to
investigate pleiotropy have been actively researched (reviewed in [32] and [29]), for example,
using linear mixed models [14, 15]. However, these methods do not allow to utilize functional
annotation data for prioritization of GWAS results. On the other hand, various statistical
methods which make use of functionally annotated SNPs have been proposed in recent years
(reviewed in [8], [4], and [40]). For example, GSEA [33] identifies potentially important path-
ways in which target genes of risk-associated SNPs are involved while RegulomeDB [3] allows
nucleotide-level annotations of risk-associated SNPs, especially for those located in non-coding
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regions. Stratified False Discovery Rate methods were applied to incorporate annotation into
GWAS data analysis [27]. However, these methods are designed for the analysis of single pheno-
type and hence, these methods do not utilize functional annotation data fully efficiently for the
genetic variants shared by multiple phenotypes. In short, well established statistical framework
for the integration of functional annotation data to the joint analysis of genetically correlated
GWAS data is still missing in the current literature.
In order to meet the emerging needs described above, we propose a unified statistical frame-
work, named GPA 1, to prioritize GWAS result based on the pleitropy and annotation infor-
mation. GPA also provides statistically rigorous and easily interpretable inference tools for the
analysis of pleiotropy and the enrichment of functional annotation. This article is organized as
follows. In Section 2, we first describe our GPA probabilistic model and its statistical inference
procedures. In Section 3, we investigate the properties of GPA using extensive simulation stud-
ies and illustrate the versatility and utility of GPA with the analysis of real data. Specifically,
we apply GPA to the five psychiatric disorder GWAS data with central nervous system gene
expression data and show that GPA can accurately identify pleiotropy structure among these
diseases. We further apply GPA to the bladder cancer GWAS data with the ENCODE DNase-
seq data from 125 cell lines and show that GPA can detect cell lines that are biologically more
relevant to the phenotype of interest. In Section 4, we conclude this paper with the discussion
of related issues.
2 Methods
2.1 GPA probabilistic model
Throughout this paper, we shall use j to index SNPs, k to index GWAS data sets, d to index the
annotation data sets. Let’s first consider the simplest case that we only have summary statistics
(p-values) from only one GWAS data set, then extend our model to handle multiple GWAS
data sets and annotation data. Suppose we have performed hypothesis testing of genome-wide
SNPs and obtained their p-values:
Null hypothesis : H
(1)
0 , H
(2)
0 , . . . , H
(j)
0 , . . . , H
(M)
0 ,
p-value : P1, P2, . . . , Pj, . . . , PM ,
(1)
where M is the number of SNPs. Consider the “two-groups model” [10], i.e., the obtained
p-values are assumed to come from the mixture of null and non-null, with probability pi0 and
pi1 = 1−pi0, respectively. Let Zj = [Zj0, Zj1] be the latent variables indicating whether the j-th
SNP is null or non-null, where Zj0 ∈ {0, 1}, Zj1 ∈ {0, 1}, and Zj0 + Zj1 = 1 (A SNP can only
be either null or non-null). Zj0 = 1 means un-associated (null) and Zj1 = 1 means associated
(non-null). Then we have the following two-groups model:
pi0 = Pr(Zj0 = 1) : (Pj|Zj0 = 1) ∼ U [0, 1],
pi1 = Pr(Zj1 = 1) : (Pj|Zj1 = 1) ∼ Beta(α, 1).
(2)
where the p-values from the null group are from the Uniform distribution on [0,1], denoted as
U [0, 1], and the p-values from the non-null group are from the Beta distribution with parameters
1“G” for GWAS, “P” for pleiotropy and “A” for Annotation.
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(α, 1), where 0 < α < 1. We put the constraint 0 < α < 1 to model that smaller p-value is
more likely than larger p-value when it is from the non-null group [23].
To incorporate information from functional annotation data, we extend the basic model as
follows. Suppose we have collected information from D functional annotation sources in the
annotation matrix: A ∈ RM×D, where Aj,d ∈ {0, 1} indicates whether the j-th SNP is annotated
in the d-th functional annotation source. For example, when there are two annotation sources:
eQTL data and DNase I hypersensitivity sites (DHS) data, then A is an M × 2 matrix. If the
j-th SNP is an eQTL, then Aj1 = 1, otherwise Aj1 = 0; if it is located in a DHS, then Aj2 = 1,
otherwise Aj2 = 0. Now we model the relationship between Zj and Ajd as
(Ajd|Zj0 = 1) ∼ Bernoulli(qd0),
(Ajd|Zj1 = 1) ∼ Bernoulli(qd1). (3)
Clearly, qd0 = Pr(Ajd = 1|Zj0 = 1) can be interpreted as the proportion of null SNPs in the
d-th annotation file, and qd1 = Pr(Ajd = 1|Zj1 = 1) corresponds to the proportion of non-null
SNPs in the d-th annotation file. Therefore, qd1 >> qd0 means that there exists enrichment in
the d-th annotation file. The statistical inference about enrichment of annotation data will be
discussed in details in Section 2.2.2.
Now we extend the above model to handle multiple GWAS data sets. To keep the notation
uncluttered, we present the model for the case of two GWAS data but the generalization to
more than two GWAS data is straightforward. In fact, our GPA model and its algorithm are
not limited by the number of GWAS data. Suppose we have p-values from two genetically
related GWAS:
p-value from GWAS1 :P11, P21, . . . , Pj1, . . . , PM1.
p-value from GWAS2 :P12, P22, . . . , Pj2, . . . , PM2. (4)
Let P ∈ RM×2 be the matrix collecting all the p-values, where Pjk denotes the p-value of the
j-th SNP in the k-th GWAS. Similarly, we introduce latent variables Zj = [Zj00, Zj10, Zj01, Zj11]
indicating the association between the j-th SNP and the two phenotypes: Zj00 = 1 means the
j-th SNP is associated with neither of them, Zj,10 = 1 means it is only associated with the first
one, Zj01 = 1 means it is associated with the second one, and Zj11 = 1 means it is associated
with both. The two-groups model (2) is extended to the following “four-groups model”:
pi00 = Pr(Zj00 = 1) : (Pj1|Zj00 = 1) ∼ U [0, 1], (Pj2|Zj00 = 1) ∼ U [0, 1],
pi10 = Pr(Zj10 = 1) : (Pj1|Zj10 = 1) ∼ Beta(α1, 1) , (Pj2|Zj10 = 1) ∼ U [0, 1],
pi01 = Pr(Zj01 = 1) : (Pj1|Zj01 = 1) ∼ U [0, 1], (Pj2|Zj01 = 1) ∼ Beta(α2, 1),
pi11 = Pr(Zj11 = 1) : (Pj1|Zj11 = 1) ∼ Beta(α1, 1) , (Pj2|Zj11 = 1) ∼ Beta(α2, 1), (5)
where 0 < αk < 1, k = 1, 2. When the genetic basis of the two phenotypes are independent
of each other (i.e., no pleiotropy), then we have pi11 = (pi10 + pi11)(pi01 + pi11) by expectation.
Therefore, the difference between pi11 and (pi10 + pi11)(pi01 + pi11) can be used to characterize
pleiotropy. Statistical inference on pleiotropy is given in Section 2.2.2.
To incorporate annotation information into multiple GWAS model (5), similarly, we model
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the relationship between Zj and Ajd as
(Ajd|Zj00 = 1) ∼ Bernoulli(qd00),
(Ajd|Zj10 = 1) ∼ Bernoulli(qd10),
(Ajd|Zj01 = 1) ∼ Bernoulli(qd01),
(Ajd|Zj11 = 1) ∼ Bernoulli(qd11), (6)
where qd00 is the probability of a null SNP being annotated, qd10 is the probability of the first
phenotype associated-SNP being annotated, qd01 is the probability of the second phenotype
associated-SNP being annotated and qd11 is the probability of jointly associated-SNP being
annotated. Assuming the independence of SNP markers, the joint distribution Pr(P,A) can
be written as
Pr(P,A) =
M∏
j=1
 ∑
l∈{00,10,01,11}
Pr(Zjl = 1)Pr(Pj,Aj|Zjl = 1)

=
M∏
j=1
 ∑
l∈{00,10,01,11}
pilPr(Pj|Zjl = 1)Pr(Aj|Zjl = 1)

=
M∏
j=1
 ∑
l∈{00,10,01,11}
pilPr(Pj|Zjl = 1)
D∏
d=1
Pr(Ajd|Zjl = 1)
 , (7)
where Pj and Aj are the j-th row of P and A; the second equation holds by assuming the
independence between Pj and Aj, conditional on Zjl; the third equation holds by further
assuming the independence between Ajd and Ajd′ for d 6= d′, conditional on Zjl.
Parameters of the GPA probabilistic model are estimated using the Expectation-Maximization
(EM) algorithm [7], which turns out to be computationally efficient because we have explicit
solutions for estimation of all the parameters in the M-step. Standard errors for parameter
estimates are estimated using the empirical observed information matrix [19]. Note that in the
GPA model, the sample size for estimating the empirical observed information matrix corre-
sponds to the number of SNPs and as a result, we have a very large sample size (∼ 106) to
accurately estimate standard errors. More details of the EM algorithm and the estimation of
standard errors are provided in Appendix.
2.2 Statistical inference
2.2.1 False discovery rate
After we estimate parameters for the GPA model, SNPs can be prioritized based on their
local false discovery rates [9]. Note that separate analysis of single GWAS data based on their
summary statistics is equivalent to the analysis of single GWAS data using GPA without any
annotation data. Hence, separate analysis of single GWAS data can be considered as a special
case of our GPA framework.
To present the local false discovery rate based on our GPA model, we begin with the simplest
case: single GWAS without annotation data, In this case, there are only two groups: null and
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non-null. The false discovery rate is defined as the probability that j-th SNP belongs to the
null group given its p-value, i.e.,
fdr(Pj) = Pr(Zj0 = 1|Pj). (8)
For joint analysis of two GWAS data sets, we are interested in the local false discovery rate of
the j-th SNP, if it is claimed to be associated with the first phenotype and the second one, i.e.,
fdr1(Pj1, Pj2) = Pr(Zj00 + Zj01 = 1|Pj1, Pj2),
fdr2(Pj1, Pj2) = Pr(Zj00 + Zj10 = 1|Pj1, Pj2). (9)
Similarly, when annotation data are available, the false discovery rates can be calculated as
fdr1(Pj1, Pj2,A) = Pr(Zj00 + Zj01 = 1|Pj1, Pj2,A),
fdr2(Pj1, Pj2,A) = Pr(Zj00 + Zj10 = 1|Pj1, Pj2,A). (10)
Then, we use the direct posterior probability approach [21] to control global false discovery rates.
More details for the estimation of false discovery rates are provided in Appendix.
2.2.2 Hypothesis testing of annotation enrichment and pleiotropy
Consider a given annotation file, we are particularly interested in the significance of its en-
richment. First, we propose to the likelihood ratio test (LRT) to assess the significance. To
keep the notation simple, we drop the index of annotation files. Specifically, the significance of
enrichment of an annotation file for single-GWAS data analysis can be assessed by the following
hypothesis:
H0 : q0 = q1 v.s. H1 : q0 6= q1. (11)
The LRT statistics is given as follows:
λ(A) =
Pr(P,A; Θˆ
(A)
0 )
Pr(P,A; Θˆ)
,
where Θˆ
(A)
0 is the parameter estimates obtained under H0 (Here the superscript A indicates the
Annotation enrichment test). Note that Θˆ
(A)
0 can be easily obtained by running the GPA algo-
rithm without incorporating the annotation data. Under the null, the test statistic −2 log λ(A)
asymptotically follows the χ2 distribution with degree of freedom df = 1 [28]. We reject H0 if
−2 log λ(A) > χ2df=1,α, where χ2df=1,α is the (1− α)-th quantile of χ2 distribution with df = 1.
For joint analysis of two GWAS with annotation data, hypotheses (11) become as
H0 : q00 = q10 = q01 = q11 v.s. H1 : not H0. (12)
Under the null, the test statistics asymptotically follows χ2 distribution with df = 3. Similarly,
the test of annotation enrichment can be extended to handle K GWAS. In this case, the test
statistics asymptotically follows χ2 distribution with df = 2K − 1 under the null.
Now we consider testing pleiotropy between two GWAS. When there is no pleiotropy, i.e., the
signals from the two GWAS are independent of each other, testing pleiotropy can be formulated
by evaluating the following hypothesis:
H0 : pi11 = pi1∗pi∗1, v.s. H1 : not H0, (13)
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where pi1∗ = pi10 + pi11, pi∗1 = pi01 + pi11. The LRT statistics is constructed as follows:
λ(P ) =
Pr(P,A; Θˆ
(P )
0 )
Pr(P,A; Θˆ)
,
where Θˆ
(P )
0 is the parameter estimates obtained under H0 (Here the superscript P indicates the
Pleiotropy test). The test statistics (−2 log λ(P )) asymptotically follows χ2 distribution with
df = 1 under the null.
3 Results
3.1 Simulation study
We first evaluated performance of GPA for parameter estimation and hypothesis testing and
compared them with some related methods using simulation studies. We followed the classical
liability threshold model [12] to simulate case-control GWAS data for two genetically correlated
diseases. For each disease, we first simulated a large cohort of individuals with genotypes of M
independent SNPs. The MAFs of these SNPs were drawn uniformly from [0.05, 0.5]. Then we
randomly chose m SNPs to be causal SNPs. The per-minor-allele effect of each causal SNP was
drawn from a normal distribution with zero-mean and variance of h
2
(1−h2)fj(1−fj)m , where h
2 is
the desired level of variance explained by all SNPs on the liability scale and fi is the MAF of the
corresponding causal SNP. We also simulated the the environmental effect on the liability scale
for each individual from a standard normal distribution (zero mean and unit variance). The
total liability for each individual was then obtained by adding up all the genetic effects and the
environmental effect. Given a desired disease prevalence B, individuals with liabilities greater
than the 1 − B quantile were classified as cases and others were classified as controls. Then
equal numbers of cases and controls were drawn from the cohort as a GWAS data set. When
simulating two diseases simultaneously, we simulated two disjoint cohorts with the same set of
SNPs. To reflect the pleiotropy effects between the two diseases, m′ causal SNPs (m′ ≤ m) were
chosen to be shared by the two diseases. The annotation status of each causal and non-causal
SNP was simulated from a Bernoulli distribution with probability of q1 and q0 respectively.
In our simulation study, the sample size of each data set, N , was set at 1000, 2000, 5000 or
10000. The number of causal SNPs m was the same for the two diseases and was set at 500,
1000 or 2000. We varied the proportion of shared causal SNPs between the two diseases, γ,
from m/M to 1. Note that γ = m/M corresponds to zero pleiotropy. The disease prevalence,
B, was fixed at 0.1 and the variance explained by all the SNPs, h2, was fixed at 0.6 for the two
diseases. Here q1 and q0 were fixed at 0.4 and 0.1, respectively.
We first evaluated SNP prioritization accuracy of GPA. Specifically, after the two data sets
were simulated, we obtained the p-value for each SNP in each disease using a one degree of
freedom χ2 test. Then we analyzed the simulated data using our GPA method in the following
four modes: 1. analyzing the two diseases separately without the annotation data; 2. analyzing
the two diseases with the annotation data; 3. analyzing the two diseases jointly without the
annotation data; 4. analyzing the two diseases jointly with the annotation data. The simulation
was repeated 50 times for each scenario. In each mode, we compared the order of the local
false discovery rates obtained using GPA against the actual causality status of the SNPs to
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Figure 1: The AUC (left) and power (right) of GPA for SNP prioritization accuracy at N =
5000, m = 1000.
calculate the area under the receiver operating characteristic curve (AUC) as a measure of
causal SNP prioritization accuracy. Figure 1 (left panel) shows the AUCs from the four modes
with N = 5000 and m = 1000 (results for other scenarios are in the supplementary material).
Because all the simulation parameters are the same for the two diseases, only the results for
the first disease is shown. The results suggest that both the annotation information and the
pleiotropy between the two diseases improved the prioritization accuracy. In particular, as the
fraction of shared causal SNPs increased, the prioritization accuracy also increased. Given the
local false discovery rates obtained using GPA, we controlled the global false discovery rate at
0.2 and calculated the average power for all the true causal SNPs. The results for N = 5000
and m = 1000 are shown in Figure 1 (right panel) and are similar with results of the AUC
(results for other scenarios are in the supplementary material, Figure S1-S11). We also checked
the actual false discovery rates and found that on average the false discovery rate was indeed
by controlled at 0.2 in spite of occasional slight conservativeness (Figure 2, Figure S12-S22).
In the simulations, we also found that GPA provided satisfactory estimate of q, the probability
of being annotated for a certain group of SNPs, as long as there are enough number of SNPs
in that group (Figure 3, Figure S23-S33). However, we note that the proportion of causal
SNPs always tends to be under-estimated (Figure 4, Figure 5, Figure S34-S55). The under-
estimation may be due to the limited sample size and the model mismatch between GPA and
the random-effects model.
As a comparison, we also tried the “conditional FDR” approach proposed by Andreassen
et al. [2] to prioritize the SNPs in our simulations. The comparison between this approach and
GPA at N = 5000 and m = 1000 is shown in Figure 6. GPA significantly outperformed the
conditional FDR approach in terms of the SNP prioritization accuracy. More importantly, when
no pleiotropy exists, the conditional FDR approach showed worse accuracy than single-GWAS
analysis using the standard FDR approach, whereas GPA achieved comparable accuracy with
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Figure 2: The global false discovery rates of GPA at N = 5000, m = 1000. The upper and
lower panels show the results (joint and separate analysis, with and without annotation) for
the first and second GWAS , respectively. For all scenarios, the global false discovery rates of
GPA are controlled at the nominal level.
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Figure 3: The estimated q at N = 5000, m = 1000. The upper panel shows the estimated
q00, q10, q01, q11 in the joint analysis of two GWAS. The lower panel show the estimated q0∗, q1∗
and q∗0, q∗1 in the separate analysis for the first and second GWAS, respectively. The red lines
represent the true values.
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Figure 4: The estimated pi of separate analysis (single GWAS) at N = 5000, m = 1000. The
upper panel shows the estimated pi0∗, pi1∗, pi∗0, pi∗1 with annotation, and the lower panel shows
the estimated pi0∗, pi1∗ and pi∗0, pi∗1 without annotation. The red lines represent the true values.
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Figure 6: The comparison of AUC between GPA and the conditional FDR approach at N =
5000, m = 1000.
single-GWAS analysis in this scenario. This suggests that GPA was able take advantage of
pleiotropy while it sacrifices much less statistical power than the conditional FDR approach
when pleiotropy does not exist.
Next, we evaluated the power and type I error of GPA for hypothesis testing on the signif-
icance of annotation enrichment in causal SNPs. Another popular method that does a similar
job is the Gene Set Enrichment Analysis (GSEA) [33]. Although GSEA typically is used for
analysis of gene expression data, its input can be a list of p-values obtained from any type of
sources. Therefore we implemented the GSEA method to test the enrichment the p-values of a
set of SNPs being annotated and compared it with GPA. We followed the previous simulation
scheme and simulated one GWAS data set with M = 20000, N varying from 2000 to 10000,
m varying from 500 to 2000. Here q0 was fixed at 0.1 and q1 was varied from 0.1 to 0.5. We
performed tests at the significance level of 0.05. Type I error rate was evaluated at q1 = 0.1
and power was evaluated in other cases. The result for n = 1000 was shown in Figure 7. We
observed that in general, GPA provided much higher power than GSEA while both methods
appropriately controlled the type I error rate.
Lastly, we evaluated the power and type I error rate of GPA for the test of pleiotropy in our
simulations. The simulation parameters were the same as in the previous simulations. Power
was evaluated at γ = 0.25, 0.5, 0.75 and 1. The type I error rate was evaluated at γ = m/M .
As shown in Figure 8, the power increases as m decreases and as N and γ increases, whereas
the type I error rate was appropriately controlled in all cases.
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αˆ pˆi0 pˆi1 qˆ0 qˆ1 qˆ1/qˆ0 p-value
ADHD 0.694 (0.103) 0.991 (0.006) 0.009 (0.006) 0.218 (0.001) 0.381 (0.055) 1.749 (0.447) 0.083
ASD 0.710 (0.014) 0.909 (0.007) 0.091 (0.007) 0.214 (0.001) 0.270 (0.009) 1.261 (0.055) 8.408e-07
BPD 0.697 (0.007) 0.821 (0.007) 0.179 (0.007) 0.202 (0.001) 0.297 (0.004) 1.467 (0.033) 1.439e-48
MDD 0.837 (0.019) 0.807 (0.027) 0.193 (0.027) 0.212 (0.003) 0.249 (0.008) 1.177 (0.058) 0.005
SCZ 0.596 (0.004) 0.804 (0.004) 0.196 (0.004) 0.203 (0.001) 0.283 (0.003) 1.391 (0.022) 7.742e-79
Table 1: Single-GWAS analysis of five psychiatric disorders using the CNS gene set as the
annotation data. Here αˆ is the estimate of α parameter of Beta distribution (2), pˆi0 and pˆi1
are the estimated proportion of null-SNPs and non-null-SNPs defined in (2), qˆ0 and qˆ1 are the
estimated proportion of null and non-null SNPs in the CNS gene set. Enrichment fold qˆ1/qˆ0
and p-value given by hypothesis testing of enrichment in annotation data are provided in last
two columns. The values in the brackets are standard errors of the estimates.
3.2 Real data analysis
3.2.1 GWAS of five psychiatric disorders
We applied our GPA model to analyze the five psychiatric disorders [5, 6]: attention deficit-
hyperactivity disorder (ADHD), autism spectrum disorder (ASD), bipolar disorder (BPD),
major depressive disorder (MDD) and schizophrenia (SCZ). Detailed information about these
data sets is provided in [5, 6]. The summary statistics of the five psychiatric disorders were
downloaded from the section of cross-disorder at the website of Psychiatric Genomics Consor-
tium (PGC) https://pgc.unc.edu/Sharing.php. The p-values were available for 1,230,535
SNPs in ADHD, 1,245,864 SNPs in ASD, 1,233,533 SNPs in BPD, 1,232,794 SNPs in MDD,
and 1,237,959 SNPs in SCZ, respectively. We took the intersection of those SNPs and ob-
tained their p-values. Finally, we had a p-value matrix P ∈ R1,219,805×5 for the five psychiatric
disorders.
First, we performed single-GWAS data analysis using genes preferentially expressed in the
central nervous system (CNS) [12, 24] as the annotation data. Specifically, we generated the
annotation vector A ∈ R1,219,805 as follows: The entries in A corresponding to SNPs exactly
in the genes from the CNS set or within 50-kb boundaries of those genes were set to be 1.
Consequently, 21.9% of the genome-wide SNP markers were annotated. The analysis results of
these five psychiatric disorders were given in Table 1. The estimated fold enrichment qˆ1/qˆ0 of
the CNS set was 1.749 (s.e. 0.447), 1.261 (s.e. 0.055), 1.467 (s.e. 0.033), 1.177 (s.e. 0.058) and
1.391 (s.e. 0.022) for ADHD, ASD, BPD, MDD and SCZ, respectively. PGC also evaluated
enrichment of the CNS gene set by variance component estimation using linear mixed models
(LMM) [5], suggesting about 1.6% and 1.5% fold enrichment in BPD and SCZ, respectively.
The minor difference of fold enrichment estimation between GPA and LMM could be under-
standable: First, GPA only used summary statistics while LMM used both phenotype and
genotype data. Second, the mathematical definition of fold enrichment is different between
GPA and LMM: GPA used the ratio between qˆ1 and qˆ0, while LMM used the ratio between the
proportion of the variance explained by SNPs in the CNS set and the proportion of the CNS
set in entire genome. Furthermore, we evaluated the significance of enrichment of the CNS set
by hypothesis testing. As given in Table 1, enrichment of the CNS gene set was strong in BPD
and SCZ, moderate in ASD and MDD, and nonsignificant in ADHD.
Next, we applied GPA to study pairwise pleiotropy of these five psychiatric disorders without
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pˆi00 pˆi10 pˆi01 pˆi11 LRT p-value
ADHD-ASD 0.900 (0.009) 0.007 (0.006) 0.093 (0.009) 0.001 (0.004) 0.913 0.339
ADHD-BPD 0.822 (0.008) 0.001 (0.005) 0.164 (0.009) 0.013 (0.007) 29.849 4.670e-08
ADHD-MDD 0.776 (0.036) 0.006 (0.010) 0.217 (0.036) 0.001 (0.010) -0.005 1
ADHD-SCZ 0.804 (0.005) 0.001 (0.004) 0.183 (0.008) 0.012 (0.007) 15.855 6.837e-05
ASD-BPD 0.791 (0.008) 0.027 (0.007) 0.115 (0.009) 0.067 (0.008) 69.391 8.074e-17
ASD-MDD 0.727 (0.033) 0.049 (0.016) 0.180 (0.033) 0.044 (0.016) 2.717 0.099
ASD-SCZ 0.771 (0.006) 0.035 (0.006) 0.131 (0.007) 0.064 (0.006) 106.493 5.749e-25
BPD-MDD 0.793 (0.014) 0.011 (0.026) 0.030 (0.015) 0.166 (0.027) 126.037 3.017e-29
BPD-SCZ 0.821 (0.004) 0.001 (0.005) 0.013 (0.006) 0.165 (0.007) 1851.727 0
MDD-SCZ 0.809 (0.009) 0.001 (0.010) 0.001 (0.025) 0.189 (0.025) 466.312 2.034e-103
Table 2: Pleiotropy estimated among five psychiatric disorders. The values in the brackets are
standard errors of the estimates. The last two columns provide the LRT statistics and p-values
of hypothesis testing (13).
using annotation data. As shown in Table 2, our analysis result suggested the pleiotropy
effect was strong between BPD and SCZ (p-value is essentially zero), MDD and SCZ (p-value
2.034× 10−103), BDP and MDD (p-value 3.017× 10−29), ASD and SCZ (p-value 5.749× 10−25),
ASD-BPD (p-value 8.074× 10−17), moderate between ADHD and BPD (p-value 4.670× 10−8),
ADHD and SCZ (6.837× 10−5), and non-significant for other pairs. Our analysis result agrees
with the most of pleiotropy results reported in [5] and the disagreement mainly came from the
joint analysis between ADHD and other disorders. The pleiotropy between ADHD and MDD
was reported to be moderate, while GPA did not detect this moderate effect. From single GWAS
analysis of ADHD, given in Table 1, the estimated parameters (pˆi1=0.009 (s.e. 0.006), αˆ=0.694)
indicates that its GWAS signal was very weak. For MDD, the estimated parameter αˆ=0.837
also indicates the weak marginal signal of MDD. Consequently, the marginal GWAS signals of
ADHD and MDD were too weak to allow GPA to detect the pleiotropy effect between them.
Since the data analysis performed in [5] used genotype data, the bivariate linear mixed model
could still have enough power to detect the moderate genetical correlation between ADHD and
MDD.
We further applied GPA to study all pairs of disorders using the CNS gene set as the
annotation data. The estimated qˆl (l ∈ {00, 10, 01, 11}) are given in Table 3 and pˆil remained
almost the same as without annotation data. The p-values of hypothesis test (12) are also
provided in the last column of Table 3. The p-value should be interpreted with caution: as
shown in Table 1, the CNS gene set is enriched in all these disorders except ADHD. Hence,
the significant p-values listed in Table 3 may be simply due to the combinatorial effects. On
the other hand, the ratio between qˆ11 and qˆ00 could be more interesting. Take BPD-SCZ as an
example. The ratio between qˆ11 and qˆ00 is 1.503 (s.e. 0.025), which suggests that enrichment of
the CNS set for the BDP-SCZ shared risk variants was even stronger than that for BPD-only
(1.467 (s.e. 0.033)) or SCZ-only (1.391 (s.e. 0.022)).
We also compared the results given by four different analysis approaches: single-GWAS
analysis with or without annotation, two-GWAS joint analysis with or without annotation data.
The manhattan plots are shown in Figure 9. For single-GWAS analysis without annotation,
GPA identified 13 SNPs and 391 SNPs with fdr < 0.05 for BPD and SCZ, respectively.
By using the CNS set as annotation, GPA was able to identify 14 and 409 SNPs for BPD
and SCZ, respectively. For joint analysis without annotation, the number of identified SNPs
dramatically increased to 383 and 821 for BPD and SCZ, respectively. By using the CNS set
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qˆ00 qˆ10 qˆ01 qˆ11 p-value
ADHD-ASD 0.212 (0.002) 0.425 (0.146) 0.272 (0.013) 0.022 (1.879) 4.205e-06
ADHD-BPD 0.202 (0.003) 0.975 (0.261) 0.304 (0.010) 0.216 (0.143) 2.965e-47
ADHD-MDD 0.209 (0.004) 0.490 (0.411) 0.251 (0.014) 0.001 (2.357) 0.005
ADHD-SCZ 0.204 (0.002) 0.001 (2.349) 0.261 (0.015) 0.511 (0.100) 7.132e-79
ASD-BPD 0.204 (0.003) 0.164 (0.073) 0.285 (0.015) 0.318 (0.022) 2.058e-51
ASD-MDD 0.193 (0.006) 0.470 (0.069) 0.309 (0.018) 0.002 (0.171) 3.251e-09
ASD-SCZ 0.199 (0.002) 0.295 (0.028) 0.296 (0.008) 0.255 (0.018) 2.078e-81
BPD-MDD 0.195 (0.004) 0.568 (0.025) 0.367 (0.066) 0.222 (0.023) 7.314e-48
BPD-SCZ 0.206 (0.001) 0.001 (6.907) 0.026 (0.720) 0.309 (0.006) 2.860e-130
MDD-SCZ 0.204 (0.002) 0.001 (16.882) 0.732 (1.019) 0.260 (0.011) 7.324e-78
Table 3: GPA results for all pairs of the five psychiatric disorders with the CNS set as annota-
tion. The estimated pˆil almost remain the same as Table 2 and qˆl are shown in the table. The
values in the brackets are standard errors of the estimates. The p-values of hypothesis testing
(12) are provided in the last column.
as annotation, the number of identified SNPs further increased to 385 and 837 for BPD and
SCZ, respectively. We investigated the result of BPD more in detail to evaluate the power of
GPA in identification of functionally important SNPs. For single-GWAS analysis of BPD, GPA
was able to identify SNPs locating the ANK3 gene. By using annotation data, the CACNA1C
gene which encodes an alpha-1 subunit of a voltage-dependent calcium channel was identified
by GPA. After incorporating pleiotropy information between SCZ and BPD, more functionally
relevant genes, such as PBRM1, C6orf136, DPCR1, SYNE1, can be further identified by GPA.
For instance, SYNE1 encodes the synaptic nuclear envelope protein 1, and provides instructions
for making a protein called Syne-1 that is found in many tissues and especially critical in the
brain. The Syne-1 protein is active (expressed) in Purkinje cells, which are located in the
cerebellum and are involved in chemical signaling between nerve cells (neurons). Mutations
in the SYNE1 gene have been found to cause autosomal recessive cerebellar ataxia type 1
(ARCA1) and SYNE1 has recently been implicated as a susceptibility gene for BPD in a large
collaborative GWAS study [31]. Clearly, these results indicate that the statistical power to
identify associated SNPs increased a lot by making use of pleiotropy and functional annotation
(in this real data example, pleiotropy played a more important role than functional annotation).
We also tried to apply GPA for joint analysis of BDP, SCZ and MDD to further explore their
joint genetic architecture. In this scenario, GPA used eight-group to model all 23 states of a
SNP, which is a nature extension of four-group model (5). However, we found that the estimated
parameters obtained from this model were not reliable because of their large standard errors.
Also, the interpretation of the estimated parameters became more complicated. Therefore, we
mainly focused on two-GWAS analysis in this paper.
Regarding to computational time, the GPA algorithm takes less than 20 minutes to analyze
typical GWAS data sets. The speed of convergence depends on the strength of the GWAS
signals. For example, it took about 7 mins and 3 mins to analyze ADHD and SCZ, repectively,
as SCZ has a stronger GWAS signal than ADHD. For joint analysis of BPD and SCZ, it took
about 20 mins. All timings were carried out on a desktop with 3.0 GHz CPU with 16G memory.
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Figure 9: Manhattan plots of BPD and SCZ. Top left panel: separate analysis without an-
notation. Top right panel: separate analysis with CNS annotation. Bottom left panel: joint
analysis without annotation. Bottom right panel: joint analysis with CNS annotation. The red
and blue lines indicate fdr = 0.05 and 0.1, respectively.
3.3 Bladder cancer GWAS and ENCODE annotation data
In molecular biology, DNase I hypersensitive sites (DHSs) are regions where DNA degradation
by enzymes like DNase I raise more frequently. As a result, DHSs can mark active transcription
regions across genome and these patterns are known to be tissue or cell specific. The ENCODE
project analyzed the DHSs in 125 human cell lines with the intention of cataloging human
regulatory DNA [35]. In this section, we applied GPA to assess how bladder cancer [25] risk
associated SNPs are enriched in DHSs region across these 125 human cell lines.
We downloaded genotype data for bladder cancer from dbGaP (NCI Cancer Genetic Markers
of Susceptibility (CGEMS) project; accession number phs000346.v1.p1). We used the samples
genotyped from both Illumina 1M chip and 610K chip for our analysis. For quality con-
trol, we removed SNPs with a missing rate > 0.01. We checked Hardy-Weinberg Equilib-
rium and excluded SNPs with p-value < 0.001. SNPs with minor allele frequency (MAF)
< 5% were also removed. Finally, 490,614 SNPs from 3,631 cases and 3,356 controls of
European descent were used in the analysis. Then, we analyzed this bladder cancer data
with logistic regression by assuming additive model and obtained p-values. We also down-
loaded the uniform peak files for DHS in 125 cell lines from the ENCODE database (http:
//genome.ucsc.edu/cgi-bin/hgFileUi?db=hg19&g=wgEncodeAwgDnaseUniform). Note that
the DHS for these 125 cell lines were identified with a uniform analysis workflow by the EN-
CODE Consortium and this facilitates fair and unbiased comparison among cell lines as anno-
tation for our GPA model.
We applied GPA to analyze the bladder cancer GWAS data set with one annotation data
at a time, and performed hypothesis testing to assess the significance of enrichment. The result
is shown in the left panel of Figure 10. Under significance level α = 0.05 after Bonferroni
correction, annotations from 19 cell lines were significantly enriched for bladder cancer risk
associated SNPs. Most of these cell lines were derived from lymphocytes from normal blood
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(e.g., T cells CD4+ Th0 adult, Monocytes CD14+ RO01746), while some cell lines came from
cancer patients (e.g., Gliobla and HeLa-S3). The above results demonstrates that the functional
roles of bladder cancer risk variants might be involved in disturbance of immune system or
carcinoma pathways. This also implies that GPA may be an effective way to explore functional
role of GWAS hits by testing enrichment on phenotype-related annotations or user-specified
annotations.
We also compared GPA with the LMM-based approach [13, 43]. Specifically, we considered
the following genome-partitioning linear mixed model:
y = Xβ + W1u1 + W2u2 + e,
u1 ∼ N (0, σ21I),u2 ∼ N (0, σ22I), e ∼ N (0, σ2eI), (14)
where X are covariates (the first five principal components from genotype data), and W1 and
W2 are sets of SNPs overlapping DHS in each cell line and the remaining SNPs, respectively.
We denote number of SNPs in W1 and W2 as M1 and M2, respectively. Median number of
SNPs that overlap DHS in each cell line is about 60K and 90% of cell lines have number of
DHS ranging between 40K and 80K. In order to take into account such variation in number
of DHS among cell lines, we defined a scaled version of the proportion of phenotype variance
explained by SNPs overlapping DHS in each cell line as
v1 =
M
M1
M1σ
2
1
(M1σ21 +M2σ
2
2 + σ
2
e)
, (15)
where
M1σ21
(M1σ21+M2σ
2
2+σ
2
e)
is the proportion of the explained variance and M
M1
is the scaling factor.
The right panel of Figure 10 shows that (−log10)-transformed p-value of the GPA annotation
enrichment test is well linearly related to v1. This indicates that our GPA model captures
enrichment of annotation almost as accurately as LMM even without the original genotype
data, which implies wide applicability of our GPA model.
4 Discussion and Conclusion
4.1 Relationship between GPA and other related methods
In this subsection, we briefly discuss the relationship of GPA with other related methods, such
as LMM, conditional FDR and GSEA.
LMM is an effective tool for exploring genetic architecture of complex traits/diseases and it
has been implemented in a popular software named GCTA [42]. Compared with LMM, GPA
has the following distinct features:
• LMM explores the genetic architecture underlying of complex trait/disease by estimating
the gross phenotypic variance that can be explained by whole genome or a certain subset of
SNPs. In contrast, GPA provides more “fine-grained” understanding by giving estimates
of the local fasle discovery rate of each SNP, the proportion of SNPs that are associated
with the phenotype ({pil}), the overall effect strength of the associated SNPs (α), and
enrichment of a particular functional annotation ({ql}).
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Figure 10: Enrichment of the DNase I hypersenstivity site annotation data from 125 cell lines
for bladder cancer. Left panel: − log(p− value) of hypothesis testing (11) vs. fold enrichment
qˆ1/qˆ0. The vertical red line corresponds to the significance level (α = 0.05) after Bonferroni
correction. The horizontal red line corresponds to ratio=1. Right panel: The normalized
variance component v1 (15) given by LMM v.s. − log(p− value) given by GPA.
• Application of LMM requires the availability of genotype data, while GPA only needs
the summary statistics (p-values) as its input. Typically, the genotype data may not be
accessible as easily as the summary statistics. For example, when researchers want to
implement the integrative analysis for their own GWAS data at hand with related GWAS
studies, it is much easier for them to obtain the summary statistics than the whole data
sets of related GWAS studies. In this sense, GPA may greatly simplify the procedure of
integrative analysis.
To our best knowledge, the conditional FDR approach is the first approach that statistically
addresses the issue of pleiotropy between two GWAS, and GSEA is the most popular approach
to evaluating the enrichment of gene sets. In fact, GPA provides a unified framework for
systematically integrating both sources of information: pleiotropy and annotation. Rigorous
statistical inference of pleiotropic effects and annotation enrichment has been established in this
framework. As demonstrated in our simulation study (based on the widely accepted random-
effects model in GWAS), GPA has better performance of identifying disease-associated markers
than the conditional FDR approach, and it shows a greater power of evaluating annotation
enrichment than GSEA as well.
4.2 Conclusion
A large number of GWAS have been carried out in the last few years. As the cumulation of
GWAS data, it is time to investigate systematic analysis of GWAS data sets to provide com-
prehensive understanding of the genetic architecture of complex traits/diseases, and provide
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new insights for functional genome studies. To achieve this goal, there have been fast growing
interests in developing computational and statistical approaches to exploring genomic data in
the post-GWAS era. In this paper, we present our approach, named GPA, which integrates
information from multiple GWAS data sets and functional annotation data. Not only has GPA
a better statistical power than related methods, it also provides interpretable model param-
eters which deepens our understanding of the genetic architecture of complex traits/diseases.
We have successfully applied GPA to analyze GWAS data of five psychiatric disorders from
PGC. The real data results demonstrate that GPA is able to identify pleiotropic effects among
psychiatric disorders and detect enrichment of the CNS gene set. We have also applied GPA to
analyze bladder cancer GWAS data with ENCODE data as annotation, where the significant
enrichment of immune system and carcinoma pathways has been observed. In addition, GPA
shows similar results of enrichment analysis to LMM, even without the genotype data. This
suggests that GPA can serve as an effective tool for the integrative analysis of multiple GWAS
data with functional annotation data, when genotype data are not available.
In this work, we mainly focused on studying the role of a single annotation vector. To deal
with multiple annotation vectors, we assumed the conditional independence among them (see
GPA model (7)). As a result, the current version of GPA may become unreliable in the presence
of multiple highly correlated annotation vectors. Hence, when multiple sources of annotation
data are available, we suggest incorporating them into GPA one at a time, as demonstrated
in our analysis of bladder cancer GWAS data with ENCODE annotation. We realize that
simultaneous analysis of multiple correlated annotation vectors may be more powerful. We will
investigate this issue in our future work.
Web source
The R package of GPA is publicly available from GitHub http://dongjunchung.github.io/GPA/
and will be available in Bioconductor upon acceptance of the manuscript.
Appendix
The Expectation-Maximization algorithm
In order to be consistent with the main text, we present the EM algorithm for the case that we
have two GWAS data but the generalization to more than two GWAS data is straightforward
and the actual GPA algorithm is not limited to the number of GWAS data. In the GPA model,
we have the parameter vector of length (2K +K + 2KD) as
Θ = (pi00, pi10, pi01, pi11, α1, α2, [qd00, qd10, qd01, qd11]d∈{1,··· ,D})
and the complete likelihood as
Lc(Θ) =
M∏
j=1
∏
l∈{00,10,01,11}
[
pilPr(Pj1, Pj2|Zjl = 1; Θ)
D∏
d=1
Pr(Ajd|Zjl = 1; Θ)
]Zjl
.
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If annotation data is not incorporated, this complete likelihood is simplified to
Lc(Θ) =
M∏
j=1
∏
l∈{00,10,01,11}
[pilPr(Pj1, Pj2|Zjl = 1; Θ)]Zjl .
Based on this complete likelihood, the E- and M-steps in t-th iteration of the EM algorithm
are obtained as follows.
E-step:
For l ∈ {00, 10, 01, 11}, posterior probabilities for association of j-th SNP are obtained as:
z
(t)
jl = Pr(Zjl = 1|P,A; Θ(t))
=
pi
(t)
l Pr(Pj1, Pj2|Zjl = 1; Θ(t))
∏D
d=1 Pr(Ajd|Zjl = 1; Θ(t))∑
l′∈{00,10,01,11} pi
(t)
l′ Pr(Pj1, Pj2|Zjl′ = 1; Θ(t))
∏D
d=1 Pr(Ajd|Zjl′ = 1; Θ(t))
.
If annotation data is not incorporated, for l ∈ {00, 10, 01, 11}, we have
z
(t)
jl = Pr(Zjl = 1|P; Θ(t)) =
pi
(t)
l Pr(Pj1, Pj2|Zjl = 1; Θ(t))∑
l′∈{00,10,01,11} pi
(t)
l′ Pr(Pj1, Pj2|Zjl′ = 1; Θ(t))
.
M-step:
Parameters for proportion of SNPs in each association status category are estimated as:
pi
(t+1)
00 =
1
M
M∑
j=1
z
(t)
j00, pi
(t+1)
10 =
1
M
M∑
j=1
z
(t)
j10, pi
(t+1)
01 =
1
M
M∑
j=1
z
(t)
j01, pi
(t+1)
11 =
1
M
M∑
j=1
z
(t)
j11.
Parameters for enrichment of d-th annotation data for association of SNPs are estimated as:
q
(t+1)
d00 =
∑M
j=1 z
(t)
j00Ajd∑M
j=1 z
(t)
j00
, q
(t+1)
d10 =
∑M
j=1 z
(t)
j10Ajd∑M
j=1 z
(t)
j10
, q
(t+1)
d01 =
∑M
j=1 z
(t)
j01Ajd∑M
j=1 z
(t)
j01
, q
(t+1)
d11 =
∑M
j=1 z
(t)
j11Ajd∑M
j=1 z
(t)
j11
.
Parameters for signal strength of GWAS data are estimated as:
α
(t+1)
1 =
∑M
j=1(z
(t)
j10 + z
(t)
j11)∑M
j=1(z
(t)
j10 + z
(t)
j11)(−logPj1)
, α
(t+1)
2 =
∑M
j=1(z
(t)
j01 + z
(t)
j11)∑M
j=1(z
(t)
j01 + z
(t)
j11)(−logPj2)
.
The M step remains the same when annotation data is not incorporated, except that we do not
need to calculate q
(t+1)
d00 , q
(t+1)
d10 , q
(t+1)
d01 , and q
(t+1)
d11 .
Estimation of false discovery rate
For analysis of single GWAS without annotation data, the local false discovery rate can be
calculated as
fdr(Pj) = Pˆr(Zj0 = 1|Pj) = pˆi0Pr(Pj|Zj0 = 1; Θˆ)
pˆi0Pr(Pj|Zj0 = 1; Θˆ) + pˆi1Pr(Pj|Zj1 = 1; Θˆ)
, (16)
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where pˆi0, pˆi1, and Θˆ are estimated from the EM algorithm.
For joint analysis of two GWAS data sets, we are interested in the local false discovery rate
of the j-th SNP, if it is claimed to be associated with the first phenotype and the second one,
i.e.,
fdr1(Pj1, Pj2) = Pˆr(Zj00 + Zj01 = 1|Pj1, Pj2) = Pr(Pj1, Pj2, Zj00 + Zj01 = 1; Θˆ)
Pr(Pj1, Pj2; Θˆ)
,
fdr2(Pj1, Pj2) = Pˆr(Zj00 + Zj10 = 1|Pj1, Pj2) = Pr(Pj1, Pj2, Zj00 + Zj10 = 1; Θˆ)
Pr(Pj1, Pj2; Θˆ)
, (17)
where
Pr(Pj1, Pj2; Θˆ) =
∑
l∈{00,10,01,11}
pˆilPr(Pj1, Pj2|Zjl; Θˆ),
Pr(Pj1, Pj2, Zj00 + Zj01 = 1; Θˆ) =
∑
l∈{00,01}
pˆilPr(Pj1, Pj2|Zjl; Θˆ),
Pr(Pj1, Pj2, Zj00 + Zj10 = 1; Θˆ) =
∑
l∈{00,10}
pˆilPr(Pj1, Pj2|Zjl; Θˆ), (18)
and {pˆil}l∈{00,10,01,11} and Θˆ are estimated parameters from the GPA model.
When annotation data are available, the false discovery rates can be calculated as
fdr1(Pj1, Pj2,A; Θˆ) = Pˆr(Zj00 + Zj01 = 1|Pj1, Pj2,A) = Pr(Pj1, Pj2,A, Zj00 + Zj01 = 1; Θˆ)
Pr(Pj1, Pj2,A; Θˆ)
,
fdr2(Pj1, Pj2,A; Θˆ) = Pˆr(Zj00 + Zj10 = 1|Pj1, Pj2,A) = Pr(Pj1, Pj2,A, Zj00 + Zj10 = 1; Θˆ)
Pr(Pj1, Pj2,A; Θˆ)
,
(19)
where
Pr(Pj1, Pj2,A; Θˆ) =
∑
l∈{00,10,01,11}
(
pˆilPr(Pj1, Pj2|Zjl; Θˆ)
D∏
d=1
Pr(Ajd|Zjl); Θˆ
)
,
Pr(Pj1, Pj2,A, Zj00 + Zj01 = 1; Θˆ) =
∑
l∈{00,01}
(
pˆilPr(Pj1, Pj2|Zjl; Θˆ)
D∏
d=1
Pr(Ajd|Zjl; Θˆ)
)
,
Pr(Pj1, Pj2,A, Zj00 + Zj10 = 1; Θˆ) =
∑
l∈{00,10}
(
pˆilPr(Pj1, Pj2|Zjl; Θˆ)
D∏
d=1
Pr(Ajd|Zjl; Θˆ)
)
. (20)
Finally, we use the direct posterior probability approach [21] to control global false discovery
rates to determine associated SNPs. Specifically, given the GPA model fitting, we first sort
SNPs by their local false discovery rates from the smallest one to the largest one. Let’s denote
local false discovery rates of these sorted SNPs as fj. We increase the threshold for local false
discovery rates, κ, from zero to one until
Fdr =
∑J
j=1 fj1 {fj ≤ κ}∑J
j=1 1 {fj ≤ κ}
≤ τ, (21)
where τ is the pre-determined bound of global false discovery rates. Finally, we determine SNPs
with corresponding fj < κ to be associated with the phenotype.
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Estimation of standard error
To understand the genetic architecture of complex traits, we are interested in the accuracy of
the estimated parameters ({pil}, {qd,l}) from the GPA model. Here we consider the standard
errors of those parameters which can be calculated from covariance matrix estimated using the
empirical observed information matrix [19]. Specifically, the empirical observed information
matrix is defined as
Ie(Θˆ; P,A) =
M∑
j=1
sj(Pj,Aj; Θˆ)s
T
j (Pj,Aj; Θˆ),
where Θˆ are the parameter estimates when the EM algorithm converges (i.e., maximum likeli-
hood estimator (MLE)),
sj(Pj,Aj; Θ) = EΘ
{
∂logLcj(Θ)
∂Θ
|P,A
}
,
and logLcj(Θ) is complete log likelihood for j-th SNP. sj(Pj,Aj; Θ) is a column vector of length
(2K − 1 +K + 2KD). The first three (2K − 1) components of sj correspond to pi10, pi01, pi11:
s
(1)
j (Pj,Aj; Θˆ) =
zˆj10
pˆi10
− zˆj00
pˆi00
, s
(2)
j (Pj,Aj; Θˆ) =
zˆj01
pˆi01
− zˆj00
pˆi00
, s
(3)
j (Pj,Aj; Θˆ) =
zˆj11
pˆi11
− zˆj00
pˆi00
,
where zˆjl = P
(
Zjl = 1|P,A, Θˆ
)
, l ∈ {00, 10, 01, 11}. The next two (K) components of sj
correspond to α1, α2:
s
(4)
j (Pj,Aj; Θˆ) = (zˆj10 + zˆj11) {logPj1 + 1/αˆ1} ,
s
(5)
j (Pj,Aj; Θˆ) = (zˆj01 + zˆj11) {logPj2 + 1/αˆ2} .
The remaining (2KD) components of sj correspond to qd00, qd10, qd01, qd11, d = 1, · · · , D:
s
(6)
j (Pj,Aj; Θˆ) = (zˆj00)(
Ajd
qˆd00
− 1− Ajd
1− qˆd00 ), s
(7)
j (Pj,Aj; Θˆ) = (zˆj10)(
Ajd
qˆd10
− 1− Ajd
1− qˆd10 ),
s
(8)
j (Pj,Aj; Θˆ) = (zˆj01)(
Ajd
qˆd01
− 1− Ajd
1− qˆd01 ), s
(9)
j (Pj,Aj; Θˆ) = (zˆj11)(
Ajd
qˆd11
− 1− Ajd
1− qˆd11 ).
The last part is simply ignored when annotation data is not incorporated.
We do not include a component corresponding to pi00 in sj(Pj,Aj; Θ) because of the re-
lationship that pi00 = 1 − pi10 − pi01 − pi11. Instead, after we estimate the empirical observed
information matrix, we estimate the standard error for pi00 using the Delta method [28] as
se(pˆi00) =
√
{g′(Θ)}T
{
Ie(Θˆ; P,A)
}−1
{g′(Θ)},
where g(Θ) = 1 − pi10 − pi01 − pi11, g′(Θ) = [−1,−1,−1,0], and 0 is the zero vector of length
(K + 2KD).
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